Skip to content
Clinical Trials – home
Not recruiting

Effect of PF-07850327 on Midazolam Pharmacokinetics in Healthy Adult Females (Non‑Childbearing) Relevant to ER+/HER2‑Positive Breast Cancer

Registered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study involves a type of breast cancer called ER+/HER2 positive breast cancer, which means the cancer cells have specific proteins that can affect growth. The medicine being tested is named vepdegestrant, identified by the code PF-07850327. It will be given as a tablet taken by mouth. The study also uses another medicine called midazolam, supplied as an oral solution. The purpose of the study is to see whether vepdegestrant changes how the body processes midazolam.

Participants are healthy adult women who cannot become pregnant. First, a single dose of vepdegestrant is taken, followed by a single dose of midazolam to measure how the body handles it. After a short break, participants take vepdegestrant every day for several days, and midazolam is given again to compare the results. Throughout the study, blood samples are collected to understand the drug’s absorption and elimination, and safety checks such as vital signs and heart monitoring are performed.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Receive First Study Medication

    You will be given the study tablet called vepdegestrant (PF-07850327). The tablet is a film‑coated tablet to be taken by mouth.

  2. Step 2

    Take Single Dose of Vepdegestrant

    On the first study day you will swallow one tablet containing 200 mg of vepdegestrant. The dose is taken once, in the morning, with a glass of water.

  3. Step 3

    Take Single Dose of Midazolam

    After the single dose of vepdegestrant and following the time interval specified by the study staff, you will take a single oral dose of midazolam solution. The dose contains 2 mg of the active substance and is taken by mouth.

  4. Step 4

    Safety Checks After Single‑Dose Period

    Following the administration of both medications, you will undergo safety assessments. These include measurement of vital signs (blood pressure, heart rate), an electrocardiogram (ECG) to record heart activity, and laboratory tests on blood samples.

  5. Step 5

    Begin Multiple Daily Dosing of Vepdegestrant

    You will start a sequence of daily doses of vepdegestrant. Each day you will take one tablet containing 200 mg of the drug, taken orally once each day as instructed.

  6. Step 6

    Take Midazolam After Multiple Doses

    On the final day of the multiple‑dose period, while you continue to take the daily vepdegestrant tablet, you will receive another single oral dose of midazolam (2 mg). This dose is given after the regular daily tablet and at the time specified by the study protocol.

  7. Step 7

    Final Safety Checks and Study Completion

    After the last administration of both medications, you will again have vital‑sign measurements, an ECG, and laboratory blood tests performed. These final assessments complete the study procedures for you.

Who can join the trial?

2 criteria

  • Female participants who cannot become pregnant (non‑childbearing potential), aged 18 years or older, and who are overall healthy based on medical history, physical exam, laboratory tests, and heart monitoring.
  • Body weight and size: a body mass index (BMI) between 16 and 32 kg/m² (BMI is a simple measure of body size) and a total body weight greater than 45 kg (about 99 lb).

Who cannot join the trial?

13 criteria

  • You must not have a current or past serious disease affecting your blood (hematological), kidneys (renal), hormones (endocrine), lungs (pulmonary), stomach or intestines (gastrointestinal), heart and blood vessels (cardiovascular), liver (hepatic), mind (psychiatric), nerves or brain (neurological), or allergies (including drug allergies). Minor seasonal allergies that are not causing symptoms are allowed.
  • You cannot have any medical or mental‑health condition, including thoughts of suicide or self‑harm within the past year, or any lab test result that the doctor thinks makes participation unsafe.
  • You must not have taken any prescription medicines, over‑the‑counter drugs, herbal supplements, or products containing grapefruit or Seville orange within the last 7 days (or for at least five times the drug’s “half‑life,” which is the time it takes for half of the medicine to leave your body).
  • You cannot be using any medicines that the study specifically lists as not allowed.
  • You must not have received any experimental drug or vaccine within the past 30 days (or for at least five half‑lives of that product).
  • A positive urine test for illegal drugs or a positive breath test for alcohol may exclude you, although one repeat test might be permitted.
  • Your blood pressure measured while lying down must be below 140 mm Hg systolic (top number) and below 90 mm Hg diastolic (bottom number) if you are under 60 years old, or below 150/90 mm Hg if you are 60 or older, after resting for at least five minutes. If the first reading is high, it must be checked two more times and the average used.
  • A standard 12‑lead heart test (electrocardiogram or ECG) must not show serious problems such as a corrected QT interval (QTc) longer than 450 milliseconds, a wide QRS complex over 120 milliseconds, a complete left bundle branch block, signs of a recent heart attack, abnormal ST‑T changes, advanced heart‑block, or very slow or very fast heart rhythms. If any of these are borderline, the ECG must be repeated twice and the average used.
  • Lab tests of liver enzymes (alanine aminotransferase ALT, aspartate aminotransferase AST) or total bilirubin must not be 1.05 times higher than the normal upper limit.
  • Your kidney function, measured by the estimated glomerular filtration rate (eGFR), must be 60 mL/min/1.73 m² or higher. The eGFR is calculated using a formula called CKD‑EPI, which estimates how well the kidneys filter blood.
  • You must not have a recent history (within the past 6 months) of alcohol abuse, repeated binge drinking, or use of illegal drugs. “Binge drinking” means having four or more alcoholic drinks within about two hours. Overall alcohol intake should stay below 14 units per week (one unit equals 8 oz of beer, 1 oz of 40% spirit, or 3 oz of wine).
  • You cannot have used tobacco or nicotine products more than the equivalent of five cigarettes per day or two tobacco chews per day.
  • You must not have had an allergic (hypersensitivity) reaction to the study medicines midazolam or vepdegestrant, or to any of the ingredients in those medicines.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Vepdegestrant

    is an experimental oral medication being studied for its effect on how the body processes other drugs. In this trial participants take a film‑coated tablet once each day. Researchers are looking to see whether vepdegestrant changes the way the body breaks down a standard medication, helping them understand any potential drug‑interaction risks.

  • Midazolam

    is a well‑known medication that relaxes the nervous system. In this study it is given as an oral liquid solution in a single dose and serves as a “probe” drug. By measuring how midazolam is absorbed and cleared from the body, scientists can determine whether vepdegestrant affects its metabolism.

What is already known about the treatment

  • Vepdegestrant

    It is taken as a film‑coated tablet swallowed orally, usually 200 mg once daily. Vepdegestrant is an experimental drug still in early clinical trials and not yet approved for general medical use. It is being studied for treating estrogen‑receptor positive, HER2‑positive breast cancer. The compound binds to the estrogen receptor and triggers its breakdown, stopping cancer cells from growing; it belongs to the class of selective estrogen receptor degraders (SERDs).

  • Midazolam

    It is supplied as an oral solution that is swallowed, delivering a dose of 2 mg per milliliter. Midazolam is an approved medication that has been widely used for many years as a sedative and anti‑anxiety agent. It is mainly used to calm patients before procedures or to treat severe anxiety. Midazolam enhances the activity of the brain chemical GABA, which slows down nerve signals; it is classified as a short‑acting benzodiazepine.

Investigated diseases

Estrogen receptor‑positive, HER2‑positive breast cancer - This breast cancer grows in cells that have receptors for estrogen and also overexpress the HER2 protein, which together stimulate tumor growth. The tumor may enlarge in the breast and spread to nearby lymph nodes. Over time cancer cells can invade surrounding tissue and travel through the bloodstream to distant sites such as bone, liver, or lung. The disease typically follows a pattern of gradual enlargement and potential metastasis if it continues to progress.
Trial detailsLast updated 19 Nov 2026
Age18+ yearsPhasePhase ITrial ID2023-508518-40-00Estimated enrolment16 patientsSponsorPfizer Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.